Guangzhou Trauer Biotechnology Co., Ltd.
Trauer Biotechnology’s Collagen Granted EU TSE CEP Certification for Pharmaceutical Substances-
Trauer Biotechnology’s Collagen Granted EU TSE CEP Certification for Pharmaceutical Substances
2026-03-25
Recently, Trauer Biotechnology’s collagen officially obtained the TSE CEP certificate issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM). 1 This achievement indicates that Trauer Biotechnology has met EDQM standards ...
Trauer Biotechnology to Showcase Medical-Grade Atelocollagen raw materials at IPhEB Russia 2026 (Booth 110)-
Trauer Biotechnology to Showcase Medical-Grade Atelocollagen raw materials at IPhEB Russia 2026 (Booth 110)
2026-03-23
Trauer Biotechnology will participate in IPhEB Russia 2026, taking place April 7–9, 2026 in Saint Petersburg , Russia. The company will exhibit at Booth 110 , presenting its portfolio of medical-grade a telocollagen raw materials for pharmaceu...
Major Breakthrough by Trauer Biotech: First-Generation Recombinant Type III Human Collagen Preparation Technology Leads a New Era in Medical Aesthetics-
Major Breakthrough by Trauer Biotech: First-Generation Recombinant Type III Human Collagen Preparation Technology Leads a New Era in Medical Aesthetics
2026-03-16
Trauer Biotech launched its f irst s elf-developed f ull - l ength t riple-heli cal Recombinant Type III Human Collagen (rhCollagen) product at The 10th National Academic Conference on Medical Collagen. Its core technical indicators have passed ri...
Trauer Biotech Welcomes Thai FDA and FTI Delegation for Exchange on Atelocollagen Innovation and Biomedical Applications-
Trauer Biotech Welcomes Thai FDA and FTI Delegation for Exchange on Atelocollagen Innovation and Biomedical Applications
2026-03-16
On March 10, Guangzhou Trauer Biotechnology Co., Ltd. (“Trauer Biotech”) welcomed a high-level international delegation, including experts from the Thai Food and Drug Administration (Thai FDA, TFDA) and business representatives from the Biotechnol...
New Launch: Low Endotoxin atelocollagen Sponge S! Raw Material (<0.02 EU/mg)-
New Launch: Low Endotoxin atelocollagen Sponge S! Raw Material (<0.02 EU/mg)
2026-03-13
In July 2024, Trauer Biotechnology launched the low endotoxin medical-grade atelocollagen sponge S (<0.02 EU/mg) for the global healthcare sector. This raw material is suitable for the design and application of implantable medical devices, integrat...
Good News! Trauer Biotech’s Self-Built Guangzhou Medical Collagen Industry Innovation Center Approved for Establishment-
Good News! Trauer Biotech’s Self-Built Guangzhou Medical Collagen Industry Innovation Center Approved for Establishment
2026-03-06
Guangzhou Manufacturing Innovation Centers serve as core carriers for industrial upgrading, focusing on key industrial sectors, integrating innovation resources from industry, academia, research, and application, and overcoming bottlenecks in core te...